RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Relmada Therapeutics EBIT 2024

Relmada Therapeutics EBIT

-117.95 M USD

Relmada Therapeutics Dividend yield

Ticker

RLMD

ISIN

US75955J4022

WKN

A2PSZF

In 2024, Relmada Therapeutics's EBIT was -117.95 M USD, a 13.74% increase from the -103.7 M USD EBIT recorded in the previous year.

The Relmada Therapeutics EBIT history

YEAREBIT (undefined USD)
2029e-
2028e38.45
2027e-105.67
2026e-180.9
2025e-127.48
2024e-117.95
2023-103.7
2022-161.25
2021-125.7
2020-60.84
2019-12.73
2018-6.92
2017-7.22
2016-16.22
2015-17.1
2014-17.1
2013-6.77
2012-0.05
2011-0.01

Relmada Therapeutics Aktienanalyse

What does Relmada Therapeutics do?

Relmada Therapeutics Inc is a biopharmaceutical company specializing in the development of medications for a variety of chronic pain and mental health disorders. The company is headquartered in New York, USA, and was founded in 2004. The history of Relmada Therapeutics Inc began with a focus on the development of NMDA receptor antagonists for the treatment of neuropathic pain. The company's main drug, d-Methadone, has been successfully tested in a Phase IIa clinical study and is now being tested in Phase IIb studies. Relmada Therapeutics Inc's business model is based on the development and commercialization of novel drugs targeting high medical needs. The company has a strong pipeline of pharmaceutical products in various clinical phases that can be used in pain management and mental health promotion. Relmada Therapeutics Inc generates revenue through the sale of patents and the out-licensing of their products to other pharmaceutical companies. In addition, the company pursues partnerships and joint ventures with other companies to further develop and market their products. Relmada Therapeutics Inc operates in three main divisions: pain therapy, mental health, and oncology. In pain therapy, the company has its main products, such as Oral Methadone and LevoCap ER, which help patients alleviate chronic pain. LevoCap ER is a long-acting, non-addictive pain medication that increases effectiveness and safety compared to other opioids. In the mental health field, Relmada Therapeutics Inc has developed QN-19, an overactive NMDA receptor blocker that represents a potential treatment option for depressive disorders. The company has also developed its new technology platform, mGluR2/3 agonists, which can be used in the treatment of anxiety and depression. In the oncology division, the company focuses on the development of innovative cancer treatments. The company is currently developing a new cancer drug that aims to overcome chemotherapy resistance. Relmada Therapeutics Inc is committed to providing innovative solutions to improve and enhance the quality of life for patients. The company relies on a strong research and development platform to develop medications targeting a variety of needs. The company is committed to continuing its research and development to provide innovative solutions that improve the treatment of chronic diseases. Answer: Relmada Therapeutics Inc is a biopharmaceutical company specializing in the development of medications for chronic pain and mental health disorders. The company is headquartered in New York, USA, and has a strong pipeline of pharmaceutical products in various clinical phases. They generate revenue through the sale of patents and partnerships with other companies, and their divisions focus on pain therapy, mental health, and oncology. They aim to provide innovative solutions to improve patient quality of life and continue research and development for better treatment options. Relmada Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Relmada Therapeutics's EBIT

Relmada Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Relmada Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Relmada Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Relmada Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Relmada Therapeutics Stock

How much did Relmada Therapeutics achieve in EBIT for the current year?

In the current year, Relmada Therapeutics has achieved an EBIT of -117.95 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Relmada Therapeutics.

How has the EBIT of Relmada Therapeutics developed in recent years?

The EBIT of Relmada Therapeutics has increased by 13.742% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Relmada Therapeutics?

The EBIT of Relmada Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Relmada Therapeutics pay?

Over the past 12 months, Relmada Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Relmada Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Relmada Therapeutics?

The current dividend yield of Relmada Therapeutics is .

When does Relmada Therapeutics pay dividends?

Relmada Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Relmada Therapeutics?

Relmada Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Relmada Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Relmada Therapeutics located?

Relmada Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Relmada Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Relmada Therapeutics from 5/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/5/2024.

When did Relmada Therapeutics pay the last dividend?

The last dividend was paid out on 5/5/2024.

What was the dividend of Relmada Therapeutics in the year 2023?

In the year 2023, Relmada Therapeutics distributed 0 USD as dividends.

In which currency does Relmada Therapeutics pay out the dividend?

The dividends of Relmada Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Relmada Therapeutics

Our stock analysis for Relmada Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Relmada Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.